- Home
- PBYI vs BBOT Comparison
PBYI vs BBOT Comparison
Compare PBYI & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | BBOT |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.2M | 442.6M |
| IPO Year | 2011 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PBYI | BBOT |
|---|---|---|
| Price | $10.30 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $24.55 |
| AVG Volume (30 Days) | 283.1K | ★ 749.8K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.93 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.33 | N/A |
| P/E Ratio | $124.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.58 | $3.27 |
| 52 Week High | $10.10 | $14.87 |
Technical Indicators
Market Signals| Indicator | PBYI | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 63.91 | 16.83 |
| Support Level | $8.90 | N/A |
| Resistance Level | N/A | $9.36 |
| Average True Range (ATR) | 0.46 | 0.24 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 94.03 | 2.27 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.